Affiliation:
1. From the Department of Medicine II, Okayama University Medical School, Okayama; Department of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.
Abstract
Purpose The role of adjuvant chemotherapy in patients with resected non–small-cell lung cancer (NSCLC) remains to be defined. This study was aimed at re-evaluating the effectiveness of adjuvant chemotherapy in patients with resected NSCLC, by performing a meta-analysis of relevant trials. Methods We performed a literature search to identify trials reported after the publication of a meta-analysis in 1995, comparing patients with NSCLC receiving chemotherapy after surgery with those undergoing surgery alone. The hazard ratio (HR) was estimated to assess the survival advantage of adjuvant chemotherapy. Results Eleven trials conducted on a total of 5,716 patients were identified by the literature search. In these trials, hazard ratio estimates suggested that adjuvant chemotherapy yielded a survival advantage over surgery alone (HR, 0.872; 95% CI, 0.805 to 0.944; P = .001). In a subset analysis, both cisplatin-based chemotherapy (HR, 0.891; 95% CI, 0.815 to 0.975; P = .012) and single-agent therapy with tegafur and uracil (UFT; HR, 0.799; 95% CI, 0.668 to 0.957; P = .015) were found to yield a significant survival benefit. The toxicities of adjuvant chemotherapy were found to be generally mild. Conclusion This is the first updated meta-analysis demonstrating the importance of cisplatin-based chemotherapy and single-agent UFT therapy as adjuvant chemotherapy in the treatment of resected NSCLC. Although the results must be carefully interpreted because of one limitation (the meta-analysis was performed with abstracted data), they raise critical issues that must be resolved in future studies.
Publisher
American Society of Clinical Oncology (ASCO)
Reference27 articles.
1. Prostaglandin E1: Not the Magic Bullet in ARDS
2. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide . Version 1.0. IARC CancerBase No. 5, Lyon, France, IARC Press, 2001
3. Revisions in the International System for Staging Lung Cancer
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
5. Xu G, Rong T, Lin P: Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: A randomized study on 70 patients. Chin Med J 113:617,2000-620,
Cited by
174 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献